Blood health (non-cancer)

On this page:

• Defitelio^B,P,O
• Fibryga^B,O
• Rebinyn^B,O

Defitelio^B,P,O

(new active substance)

Medical ingredient:

Defibrotide

Indication:

Defitelio is used to treat a condition called hepatic venoocclusive disease, in which the blood vessels in the liver become damaged and obstructed by blood clots.

For more information, see the Regulatory Decision Summary.

Fibryga (formerly Fibryna)^B,O

Medical ingredient:

Fibrinogen (human)

Indication:

Fibryga is used for the treatment of acute bleeding episodes and perioperative prophylaxis in children and adults with congenital afibrinogenemia and hypofibrinogenemia.

For more information, see the Regulatory Decision Summary.

Rebinyn^B,O

(new active substance)

Medical ingredient:

Coagulation Factor IX (Recombinant), Pegylated

Indication:

Rebinyn is used to treat and prevent bleeding in patients with hemophilia B (also called congenital factor IX deficiency).

For more information, see the Regulatory Decision Summary.

Health Canada approved six new generic drugs for blood health (non-cancer).

Health Canada released three risk communications for blood health (non-cancer).